Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 07/09 10:59:59 am
2339 DKK   +1.70%
07/08Genmab A/S - Major Shareholder Announcement
AQ
07/07Major Shareholder Announcement
GL
07/06GENMAB A/S : - Major Shareholder Announcement
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/03/2020 07/06/2020 07/07/2020 07/08/2020 07/09/2020 Date
2220(c) 2263(c) 2273(c) 2300(c) 2334(c) Last
143 014 184 393 132 871 162 985 166 959 Volume
-0.22% +1.94% +0.44% +1.19% +1.48% Change
More quotes
Financials
Sales 2020 9 539 M 1 446 M 1 446 M
Net income 2020 4 631 M 702 M 702 M
Net cash position 2020 13 214 M 2 004 M 2 004 M
P/E ratio 2020 31,7x
Yield 2020 -
Sales 2021 7 831 M 1 188 M 1 188 M
Net income 2021 2 723 M 413 M 413 M
Net cash position 2021 16 182 M 2 454 M 2 454 M
P/E ratio 2021 54,3x
Yield 2021 -
Capitalization 150 B 22 843 M 22 790 M
EV / Sales 2020 14,4x
EV / Sales 2021 17,1x
Nbr of Employees 579
Free-Float 94,7%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (58.8%); - income from research and development (34.8%); - other (6.4%): primarily income from partnership agreement. At the end of 2019, the group had a portfolio of 18 products in... 
More about the company
Surperformance© ratings of Genmab A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB A/S
07/08Genmab A/S - Major Shareholder Announcement
AQ
07/07Major Shareholder Announcement
GL
07/06GENMAB A/S : - Major Shareholder Announcement
AQ
07/03Major Shareholder Announcement
GL
07/02GENMAB A/S : has published its Articles of Association
AQ
06/30GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
06/29Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial o..
GL
06/12GENMAB A/S : has published its Articles of Association
AQ
06/11ABBVIE : and Genmab Announce Broad Oncology Collaboration
AQ
06/10AbbVie Up Nearly 2%, on Pace for Highest Close Since July 2018 -- Data Talk
DJ
06/10AbbVie, Genmab Unveil Oncology Collaboration
DJ
06/10Genmab and AbbVie Announce Broad Oncology Collaboration
GL
06/05GENMAB A/S : Announces European Marketing Authorization for the Subcutaneous For..
AQ
06/04Genmab Gets Europe OK for Subcutaneous Darzalex in Multiple Myeloma
DJ
06/04Genmab Announces European Marketing Authorization for the Subcutaneous Formul..
GL
More news
News in other languages on GENMAB A/S
07/08Genmab A/S - Major Shareholder Announcement
07/07Major Shareholder Announcement
07/06GENMAB A/S : - Major Shareholder Announcement
07/03Major Shareholder Announcement
07/02GENMAB A/S : has published its Articles of Association
More news
Stock Trading Strategies
GENMAB A/S - 06/15
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 107,95 DKK
Last Close Price 2 300,00 DKK
Spread / Highest target 12,2%
Spread / Average Target -8,35%
Spread / Lowest Target -41,1%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S55.25%22 843
GILEAD SCIENCES, INC.16.36%94 843
VERTEX PHARMACEUTICALS35.15%76 725
REGENERON PHARMACEUTICALS70.54%65 029
WUXI APPTEC CO., LTD.53.97%31 931
BEIGENE, LTD.23.13%15 937